肿瘤坏死因子样凋亡微弱诱导剂在原发性肝癌患者血清中的表达及其意义

目的：探讨血清肿瘤坏死因子样凋亡微弱诱导剂（sTWEAK）在原发性肝癌患者中的表达，分析sTWEAK和患者病理学指标之间的关系。方法：ELISA法检测50名健康自愿者及114例原发性肝癌患者血清sTWEAK表达水平，并分析临床病理学关系。结果：原发性肝癌患者血清sTWEAK表达水平（56．22±1．90）ng／mL明显高于健康人群（41．26±2．60）ng／mL（P〈0．0001）；原发性肝癌患者血清sTWEAK表达水平和患者肿瘤大小、肿瘤的Edmondson分级、TNM分期以及意大利评分标准密切相关（P〈0．05）。结论：原发性肝癌患者sTwEAK表达水平可以作为评估肿瘤分级以及判断患者预后的一个潜在指标。抑制原发性肝癌患者sTwEAK产生或者释放也许可以作为治疗原发性肝癌的一个潜在方法。

Expressin of serum tumor necrosis factor like apoptosis weak inducer in hepatocellulan carcinoma

Objective： The role of serum tumor necrosis factor （TNF）like weak inducer of apoptosis（sTVVEAK） in hepatocellular carcinoma is unknown. The aim of study was to evaluate con- tributions of sTVVEAK in hepatocellular carcinoma, and analyse the correlation between sTWEAK and clinicopathologic outcomes. Methods： sTWEAK levels were analysed in 50 healthy volunteers and 112 patients with hepatocellular carcinoma by ELISA analysis. Edmondson grade, TNM stage and the Cancer of the Liver Italian Program score were used as analysis variables. Results： The sTWEAK levels in hepatocellular carcinoma （56.22 ± 1.90）ng/mL was significantly higher than that in healthy control （41.26± 2.60）ng/mL（P〈0.0001）, and positive correlation were found between sTWEAK and the size of tumour （P〈0.05）. High sTWEAK level were significant differences among Edmondsongrade I, Ⅱ, Ⅲ, IV; TNM stage I , Ⅱ, Ⅲ, IV and Cancer of the Liver Italian Program score 0 1 points, 2 4 points, 〉4 points （P〈0.05, respectively）. Conclusion： These results suggest that sTVVEAK may be a useful marker for evaluating the tumour stage and predicting prognosis in hepatocellular carci- noma. Targeting sTWEAK production or release might have potential approaches for hepatocellular carcinoma treatment.